These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32889347)

  • 21. Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia.
    Kokenberg E; van der Steuijt K; Löwenberg B; Nooter K; Sonneveld P
    Haematol Blood Transfus; 1987; 30():283-7. PubMed ID: 3476358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
    Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
    Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.
    Hempel G; Relling MV; de Rossi G; Stary J; De Lorenzo P; Valsecchi MG; Barisone E; Boos J; Pieters R
    Pediatr Blood Cancer; 2010 Mar; 54(3):355-60. PubMed ID: 19731319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
    Tidefelt U; Sundman-Engberg B; Paul C
    Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis.
    Hempel G; Schulze-Westhoff P; Flege S; Boos J
    J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(2):221-8. PubMed ID: 11486832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles.
    Ahmad N; Ahmad R; Alam MA; Ahmad FJ; Amir M; Pottoo FH; Sarafroz M; Jafar M; Umar K
    Int J Biol Macromol; 2019 May; 128():825-838. PubMed ID: 30690115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
    Kokenberg E; Sonneveld P; Sizoo W; Hagenbeek A; Löwenberg B
    J Clin Oncol; 1988 May; 6(5):802-12. PubMed ID: 3163363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.
    Bains OS; Takahashi RH; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2008 May; 36(5):904-10. PubMed ID: 18276838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
    Krogh-Madsen M; Bender B; Jensen MK; Nielsen OJ; Friberg LE; Honoré PH
    Cancer Chemother Pharmacol; 2012 May; 69(5):1155-63. PubMed ID: 22212298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
    Fassas A; Anagnostopoulos A
    Leuk Lymphoma; 2005 Jun; 46(6):795-802. PubMed ID: 16019523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
    Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
    J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.
    Andersson B; Andersson I; Beran M; Ehrsson H; Eksborg S
    Cancer Chemother Pharmacol; 1979; 2(1):15-7. PubMed ID: 498413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
    Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
    Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
    Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
    Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent inhibition of human carbonyl reductase 1 (CBR1) by the prenylated chalconoid xanthohumol and its related prenylflavonoids isoxanthohumol and 8-prenylnaringenin.
    Seliger JM; Martin HJ; Maser E; Hintzpeter J
    Chem Biol Interact; 2019 May; 305():156-162. PubMed ID: 30849340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.
    Thompson P; Wheeler HE; Delaney SM; Lorier R; Broeckel U; Devidas M; Reaman GH; Scorsone K; Sung L; Dolan ME; Berg SL
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):831-8. PubMed ID: 25119182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
    Pirolli D; Giardina B; Mordente A; Ficarra S; De Rosa MC
    Eur J Med Chem; 2012 Oct; 56():145-54. PubMed ID: 22982121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
    Kearns CM; Blakley RL; Santana VM; Crom WR
    Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
    Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
    Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.